A Study of Olverembatinib in SDH-deficient GIST.
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
Overview
A Study of Olverembatinib in SDH-deficient GIST. is a phase 3 interventional study registered as NCT06640361 by Ascentage Pharma Group Inc., with 40 participants planned, started 2024-11-11. Conditions listed: GIST. No results are recorded here; the registry entry is the source.
Setting
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)
Phase
Phase 3
Sponsor
Ascentage Pharma Group Inc.
Registry
Enrolled
40
Similar pages
not linked directly; found by shared links- TrialA Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Shares Olverembatinib, Ascentage Pharma.
- TrialStudy of Olverembatinib (HQP1351) in Patients With CML-CP
Shares Olverembatinib, Ascentage Pharma.
- TrialStudy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Shares Olverembatinib, Ascentage Pharma.
- TargetBCR::ABL1 (Philadelphia chromosome)
Shares Olverembatinib, Ascentage Pharma.
- CancerChronic myeloid leukaemia (CML)
Shares Olverembatinib, Ascentage Pharma.